Antipsychotic and antidepressant weight gain

Which drugs cause weight gain and how much

Antipsychotics (ordered high to low weight gain risk):

• Olanzapine (Zyprexa): highest. Mean weight gain 5 to 10 kg (10 to 20 pounds) in the first year in most trials, with a substantial subset gaining much more.
• Clozapine (Clozaril): high. Similar to olanzapine in trials.
• Quetiapine (Seroquel): moderate. Mean 2 to 5 kg in first year.
• Risperidone (Risperdal): moderate. Mean 2 to 4 kg.
• Paliperidone (Invega): moderate.
• Iloperidone (Fanapt): moderate.
• Asenapine (Saphris): low-moderate.
• Aripiprazole (Abilify): low. Mean 1 to 2 kg.
• Brexpiprazole (Rexulti): low.
• Cariprazine (Vraylar): low.
• Ziprasidone (Geodon): minimal to none.
• Lurasidone (Latuda): minimal.
• Lumateperone (Caplyta): minimal.
• Cobenfy (xanomeline-trospium): no significant weight gain in EMERGENT trials.

First-generation antipsychotics are variable. Chlorpromazine and thioridazine (low-potency) cause substantial weight gain. Haloperidol and fluphenazine (high-potency) cause less.

Mood stabilizers: valproate (Depakote) causes substantial weight gain, sometimes 10+ kg in the first year. Lithium causes moderate weight gain, roughly 4 to 7 kg over a year, partly via increased thirst and hydration. Lamotrigine is weight neutral. Carbamazepine and oxcarbazepine are weight neutral to mildly gain-associated.

Antidepressants:

• Mirtazapine (Remeron): highest antidepressant weight gain, mean 3 to 4 kg in first year.
• Some TCAs (amitriptyline, doxepin): weight gain via histamine and 5-HT2C antagonism.
• Paroxetine (Paxil): highest weight gain among SSRIs in longer-term data.
• Other SSRIs and SNRIs: mild or absent short-term weight effect, but many patients gain 5 to 10 pounds over 1 to 2 years.
• Bupropion (Wellbutrin): weight neutral or weight loss. Sometimes used for depression specifically when weight is a concern.

Mechanism

Weight gain from psychiatric medications has multiple mechanisms:

• 5-HT2C antagonism increases appetite and food-seeking behavior. Olanzapine, clozapine, and mirtazapine all have strong 5-HT2C antagonism.
• H1 (histamine) antagonism increases appetite and reduces energy expenditure. Olanzapine, clozapine, quetiapine, mirtazapine, and TCAs all have strong H1 antagonism.
• Muscarinic M3 antagonism may impair insulin release and glucose regulation.
• Direct metabolic effects on lipid and glucose regulation independent of appetite.
• Increased sedation reduces physical activity.
• Reduced motivational drive in patients with negative symptoms of schizophrenia contributes.

Clinical impact

The metabolic burden of atypical antipsychotics is a leading cause of premature mortality in schizophrenia. Patients with schizophrenia have life expectancy 15 to 20 years shorter than the general population, and cardiovascular disease is the largest contributor. Antipsychotic weight gain contributes directly.

Rates of diabetes among schizophrenia patients on second-generation antipsychotics are 15 to 20 percent, roughly double the general-population rate. Rates of metabolic syndrome are 30 to 40 percent.

The ADA/APA/AACE/NAASO consensus (2004) established the reference monitoring schedule for atypical antipsychotics. See our metabolic monitoring schedule generator.

Management

Prevention with concurrent metformin: Aoife Carolan et al. (Schizophrenia Bulletin) meta-analysis supports starting metformin 500 to 1000 mg twice daily at the same time as high-risk antipsychotics (olanzapine, clozapine) to blunt weight gain. Effect size is meaningful; several kilograms of weight gain avoided over a year.

Switching to a lower-risk drug: for patients on olanzapine or quetiapine who have gained substantial weight, switching to aripiprazole, brexpiprazole, ziprasidone, lurasidone, lumateperone, or Cobenfy is a legitimate option. Weight often plateaus or decreases modestly after the switch, though pre-existing weight is not usually lost.

GLP-1 receptor agonists: Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are increasingly used for antipsychotic-induced weight gain. Early real-world data suggests substantial benefit. Off-label for the psychiatric indication but often covered by insurance for the resulting obesity or diabetes.

Lifestyle intervention: nutrition counseling, structured exercise programs, and behavioral weight management have modest but real effects. Effect size smaller than pharmacologic interventions but always appropriate.

Bariatric surgery: for patients with severe weight gain and comorbid metabolic disease, bariatric surgery is used and does not appear to worsen psychiatric outcomes when patients are carefully selected.

For antidepressant-induced weight gain, switching to bupropion is often the simplest intervention when the antidepressant response can be maintained.

Common questions

How much weight will I gain on olanzapine? Mean weight gain in the first year is 5 to 10 kg (10 to 20 pounds). A substantial subset gains much more, sometimes 20 kg or more. Individual variation is large. Rate of gain is fastest in the first 3 to 6 months and slows after that.

Does everyone gain weight on antipsychotics? No. Aripiprazole, brexpiprazole, ziprasidone, lurasidone, lumateperone, and Cobenfy have minimal weight gain in trials. For patients where weight is a top priority, these are legitimate first choices. See the Cobenfy state of practice for the newest option.

Should I take metformin from the start? Consensus is moving toward yes for patients starting olanzapine or clozapine, per the Carolan et al. meta-analysis. Metformin co-commencement blunts weight gain more effectively than waiting until weight gain occurs. Discuss with the prescriber; this is not universal practice yet.

Does Ozempic work for antipsychotic weight gain? Early real-world data suggests yes. Semaglutide 0.5 to 2.4 mg weekly produces meaningful weight loss in patients on antipsychotics. Insurance coverage depends on documented obesity or diabetes; the psychiatric indication is off-label.

Can I switch off olanzapine to lose the weight? Switching to a lower-metabolic-risk drug (aripiprazole, ziprasidone, lumateperone, Cobenfy) can prevent further gain and sometimes produces modest weight loss. Pre-existing weight is not usually lost through drug switch alone. Combining switch with GLP-1 agonist and lifestyle intervention gives the largest effect.

Does mirtazapine really cause that much weight gain? Yes. Mean 3 to 4 kg in the first year, sometimes much more. This is why mirtazapine is often used specifically for patients with anorexia, cachexia, or geriatric weight loss where weight gain is desired.

Do SSRIs cause weight gain long-term? Short-term (up to 6 months): minimal. Long-term (1 to 2 years): many patients gain 5 to 10 pounds. Paroxetine causes more long-term weight gain than other SSRIs. Whether the SSRI itself causes the weight gain or reversal of depression-related weight loss is complicated.

Sources

• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696.
• American Diabetes Association, American Psychiatric Association, AACE, NAASO. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
• Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71(3):377-382.
• Carolan A, Hynes-Ryan C, Agarwal SM, et al. Metformin for the prevention of antipsychotic-induced weight gain in adult psychiatric populations: a systematic review and meta-analysis. Schizophr Bull. 2024.
• Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder. JAMA Psychiatry. 2017;74(7):719-728.
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114-126.